There were 695 press releases posted in the last 24 hours and 154,046 in the last 365 days.

Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors

VANCOUVER, British Columbia and BOSTON, April 17, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that Dr. Ashish M. Kamat has joined its Scientific Advisory Board.

Dr. Kamat has been named by Expertscape as the world’s top-rated expert in urinary bladder neoplasms. Dr. Kamat has extensive experience with cystoscopic procedures, has been a principal investigator for multiple oncology and urology clinical studies for both drugs and devices, and has been involved in blue light cystoscopy studies since 2007.

Dr. Kamat is an Endowed Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center (MDACC); Associate Cancer Center Director, RFHNH in Mumbai, and President of International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the American Urological Association Leadership Program.

Dr. Kamat received his medical degree at the University of Bombay, India’s Seth G. S. Medical College & King Edward Memorial Hospital and completed a fellowship in Urologic Oncology at the MD Anderson Cancer Center. Dr. Kamat focuses on bladder cancer, immunotherapy and organ sparing therapies.  He has led several national and international studies, which have been reported in high impact journals. Dr. Kamat has over 300 publications, is listed in 'Who's Who in Medicine' and ‘Best Doctors in America’, and has won the ‘Compassionate Doctor Award’ from patient groups.

“The advent of enhanced cystoscopy, especially photodynamic diagnosis, has provided us with a means to better detect, diagnose and treat our patients who have bladder cancer,” said Dr. Kamat. “The technology being developed by the team at Imagin has the potential to allow this technology to be adopted by many centers which currently are not able to do so.”

“We are honored to have Dr. Kamat, a worldwide bladder cancer expert, join our Scientific Advisory Board,” said Jim Hutchens, Imagin’s President and CEO. “Dr. Kamat has extensive experience with cystoscopy, so his expertise will be invaluable as we progress the development of the Company’s i/Blue Imaging System.”

“I am excited to join Imagin’s Scientific Board of Advisors and look forward to supporting Imagin as it advances i/Blue to commercialization,” said Dr. Kamat.

About Imagin Medical

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company believes its first product, the i/BlueTM Imaging System, will dramatically improve surgeons’ ability to visualize cancerous cells by producing higher-quality images more quickly compared with current methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs patented ultrasensitive imaging technology and offers easy-to-use viewing options for more accurate resection. The Company’s initial focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected.  Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contacts:

Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com

Jim Hutchens, President & CEO
Telephone: 833-246-2446

/EIN News/ --

Imagin_logo.jpg

Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.